Response to the selective RET inhibitor selpercatinib (LOXO-292) in a patient with RET fusion-positive atypical lung carcinoid.
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
0
Citations
NaN
KQI